Dr No (or Not Yet)

A resourceful Australian agent seeks the cure to the persistent symptoms of Fibromyalgia (…and the disruption of the American space program!)Dr No

I’m part of the study!…Not sure what part, though.

No longer is Lyrica, Voltaren, Tramadol, Endone or anything stronger than Panadol living in my pill organiser. I have been weened off everything.

Today, I went for my second appointment at Emeritus Research. I had pretty much written-off my weekend, just in case I had side effects from whichever drug they put me on but (please press)

Today I was shown how to use my electronic diary…and that’s it. How disappointing: I have to wait ‘til next week before I start whichever regime I have been randomly chosen to undertake. I will be (randomly) assigned to one of 4 groups: Placebo, 300mg Lyrica, 15mg Mirogabalin or 30mg Miroglabin. There will be regular check-ups for the entire time.

So, until next week…

NOTE: Emeritus Research is still recruiting for the study, if anybody is interested. Click for  the Consent Form and information. Contact Daiichi using this email address – SM_DS5565_FM_Info@incresearch.com.

As well as the 1000 person study in the US and Canada, Daiichi is also recruiting in:

  • Campse and Coffs Harbour, NSW, Australia;
  • Maroochydore, Sherwood and Southport, Queensland, Australia;
  • Hobart, Tasmania, Australia;
  • Malvern East, Victoria, Australia;
  • Tallin and Tartu, Estonia;
  • Baldone, Jekabpils, Liepaja, Ogre and Riga, Latvia;
  • Auckland, Hamilton, Nelson, Tauranga and Wellington, New Zealand;
  • Banska Bystrica, Bratislava and Dubnica Nad Vahom, Slovakia; and,
  • Reading, Berkshire; Chesterfield, Derbyshire; Wellingborough, Northamptonshire: Atherstone, Warwickshire; and
  • Belfast, United Kingdom.

strip

Shaken…not Stirred

Purple bondI’m 007…really! That’s my identification number for the Daiichi Sankyo Mirogabalin study. Today, I went for my screening interview.

I got to Emeritus Research at 11am. The place looks like any other office…with 3 assessment rooms at the back, filled with medical equipment. It seems a little disorganised and haphazard; but I’m looking forward to being involved.

I had a meeting with a nurse practitioner and a doctor. They took a very, very long history, asking questions about almost EVERYthing to do with my medical history (including a questionnaire called the MINI, which I must say is just plain stupid!). I was required to give a urine sample (to check if I am pregnant), some blood work and an EKG. The doctor did a relatively quick physical and, of course, checked all my pressure points. All in all, with a few technical issues, it took about 2 hours.

The first part of the study is 13 weeks long. I have to come off the Lyrica that I am already on. Then I will be (randomly) assigned to one of 4 groups: Placebo, 300mg Lyrica, 15mg Mirogabalin or 30mg Miroglabin. There will be regular check-ups for the entire time.

After the 13 week trial, there may be an opportunity to enter the 52 week Miroglabin trial.

So, now, I’m waiting two weeks to see if I’m part of the study.

NOTE: Emeritus Research is still recruiting for the study, if anybody is interested. Click for  the Consent Form and information. Contact Daiichi using this email address – SM_DS5565_FM_Info@incresearch.com.

As well as the 1000 person study in the US and Canada, Daiichi is also recruiting in:

  • Campse and Coffs Harbour, NSW, Australia;
  • Maroochydore, Sherwood and Southport, Queensland, Australia;
  • Hobart, Tasmania, Australia;
  • Malvern East, Victoria, Australia;
  • Tallin and Tartu, Estonia;
  • Baldone, Jekabpils, Liepaja, Ogre and Riga, Latvia;
  • Auckland, Hamilton, Nelson, Tauranga and Wellington, New Zealand;
  • Banska Bystrica, Bratislava and Dubnica Nad Vahom, Slovakia; and,
  • Reading, Berkshire; Chesterfield, Derbyshire; Wellingborough, Northamptonshire: Atherstone, Warwickshire; and
  • Belfast, United Kingdom.

strip

It’s a Knock Out?

Daiichi Sankyo, a Japanese drug company, is confident it’s struck gold with its’ new drug, Mirogabalin. Daiichi Sankyo believes it will be more potent, have fewer side-effects and be longer-acting than Lyrica. That’s could be a one-two punch combination for many of usmouse who either didn’t derive benefit from the Lyrica or not enough benefit to stay on it.

A major fibromyalgia drug trial is underway in the U.S and Canada. (Want to be part of it? Contact Daiichi using this email – SM_DS5565_FM_Info@incresearch.com. Ninety-four study locations are present in the U.S. and Canada.).

Daiichi Sankyo believes mirogabalin is a significant upgrade on Lyrica. A 2014 study suggested that mirogabalin’s may be 17 times more potent than Lyrica. Both drugs bind to calcium channels that have been implicated in the production of neuropathic pain. Mirogabalin is believed to bind to a calcium channel subunit that has strictly analgesic properties. Lyrica, on the other hand, also binds to another subunit that has central nervous system effects – this is what may be responsible for its side effects.

A 1,000 person U.S./Canadian trial is assessing mirogabalin’s effectiveness in fibromyalgia. The trial makeup – putting the two drugs head to head – indicates Daiichi wants to topple the frontrunner and install mirogabalin as the preferred drug for FM.

Read more: The Next Lyrica? Thousand Person Fibromyalgia Drug Trial is Underway

strip